XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.1
The Company and Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended
Mar. 31, 2022
EUR (€)
shares
Mar. 31, 2022
USD ($)
shares
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Accumulated deficit       $ (98,961,000) $ (97,750,000)
Current liabilities exceeding current assets | € € 67,946        
Convertible debt | € € 64,110,000        
Preferred stock shares authorized | shares 5,000,000     5,000,000 5,000,000
Potentially shares issuable | shares 775,330,552 775,330,552 729,580,955    
Sub award grant revenue USD   $ 536      
Sub award grant revenue euro   482      
Total grant revenue   5,930,000      
Sub award project cost USD   2,361      
Sub award project cost euro   2,230      
Project cost   8,850,000      
Professional fees   17 $ 6    
Carrying amount   $ 67,573      
Weighted-average shares outstanding, basic and diluted | shares 303,757,622 303,757,622 303,757,622    
Grant Revenue [Member]          
Concentration risk percentage 98.00% 98.00% 99.00%    
NIH [Member]          
Grant revenue | € € 1,547,000        
First Year [Member]          
Sub award project cost USD   $ 547      
Sub award project cost euro   542      
Project cost   1,940,000      
Grant revenue   1,190,000      
Second Year [Member]          
Sub award project cost USD   870      
Project cost   1,856,000      
Grant revenue   1,052,000      
Third Year [Member]          
Sub award project cost USD   1,078      
Project cost   1,720,000      
Grant revenue   $ 1,078,000      
Stock Option [Member]          
Potentially shares issuable | shares 25,750,000 25,750,000 25,750,000    
Convertible Loans [Member]          
Potentially shares issuable | shares 740,430,633 740,430,633 738,730,875